India · Delayed Price · Currency is INR Laurus Labs Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY 2027 saw record revenue and profit growth, led by a 69% surge in CDMO sales and strong Affordable Medicines performance. Margins expanded, CapEx guidance was raised to INR 2,000 crores, and the business remains well-diversified with robust global demand.
Fiscal Year 2026
-
The AGM highlighted strong financial performance, robust margins, and continued growth in CDMO and antiretroviral segments. Strategic investments in technology and sustainability were emphasized, with shareholders approving all resolutions and management addressing key risks and future growth plans.
-
FY 2026 delivered 23% revenue growth, 26.8% EBITDA margin, and 148% PAT growth, driven by strong CDMO and generics performance. Major CapEx projects and capacity expansions support continued growth, with robust order books and resilient supply chains.
-
Q3 FY2026 saw robust revenue and margin growth, led by generics and CDMO, with strong ARV performance and continued investments in advanced manufacturing and R&D. Gross margins are expected to remain stable, and CapEx will exceed INR 1,000 crores annually.
-
Q2 FY26 saw 35% revenue growth, margin expansion, and robust ARV and CDMO performance. Major CapEx and new Vizag facility support long-term growth, with strong demand across segments and improving return ratios.
-
Q1 FY26 delivered 31% revenue growth, margin expansion, and strong CDMO momentum, with major capacity investments and a robust project pipeline supporting future growth. Gross margins are expected to remain high as CDMO share increases.
Fiscal Year 2025
-
FY2025 saw strong revenue and profit growth, driven by robust CDMO and generics performance, margin expansion, and strategic investments in technology and capacity. The outlook for FY2026 is positive, with stable ARV revenues, rising non-ARV formulations, and continued margin improvement.
-
Q3 saw strong revenue and margin growth, led by robust CDMO and formulations performance, while API revenues declined due to lower ARV volumes. Strategic investments and capacity expansions are set to drive future growth, with CDMO and Laurus Bio divisions positioned for significant medium-term gains.
-
Revenue remained flat at INR 1,224 crore in Q2 FY25, with strong CDMO growth offset by declines in ARV and oncology APIs. Gross margin held at 54-55%, EBITDA margin at 15%, and H2 is expected to drive growth and margin improvement, targeting 20% EBITDA for FY25.
-
Q1 FY25 saw flat revenue growth with strong gross margins and subdued EBITDA due to growth investments. CDMO and oncology APIs drove segment performance, while ARV revenues remained stable. H2 FY25 is expected to see improved performance, with major CapEx focused on CDMO and FDF expansion.